CERO 📈 CERo Therapeutics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
CERO: Autologous T Cell, Engineered Therapeutics, Cancer Treatments
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California. Web URL: https://www.cero.bio
Additional Sources for CERO Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CERO Stock Overview
| Market Cap in USD | 5m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2024-02-15 |
CERO Stock Ratings
| Growth 5y | -75.5% |
| Fundamental | -5.03% |
| Dividend | - |
| Rel. Strength Industry | - |
| Analysts | - |
| Fair Price Momentum | 3.21 USD |
| Fair Price DCF | - |
CERO Dividends
No Dividends PaidCERO Growth Ratios
| Growth Correlation 3m | -46.6% |
| Growth Correlation 12m | -93.7% |
| Growth Correlation 5y | -31.5% |
| CAGR 5y | -83.43% |
| CAGR/Mean DD 5y | -2.98 |
| Sharpe Ratio 12m | -1.10 |
| Alpha | -82.79 |
| Beta | -1.03 |
| Volatility | 261.73% |
| Current Volume | 998.7k |
| Average Volume 20d | 1005.8k |
What is the price of CERO stocks?
As of January 10, 2025, the stock is trading at USD 3.70 with a total of 998,700 shares traded.
Over the past week, the price has changed by -39.34%, over one month by -66.18%, over three months by -62.24% and over the past year by +3251.45%.
As of January 10, 2025, the stock is trading at USD 3.70 with a total of 998,700 shares traded.
Over the past week, the price has changed by -39.34%, over one month by -66.18%, over three months by -62.24% and over the past year by +3251.45%.
Is CERo Therapeutics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, CERo Therapeutics is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.03 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CERO as of January 2025 is 3.21. This means that CERO is currently overvalued and has a potential downside of -13.24%.
Neither. Based on ValueRay Fundamental Analyses, CERo Therapeutics is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.03 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CERO as of January 2025 is 3.21. This means that CERO is currently overvalued and has a potential downside of -13.24%.
Is CERO a buy, sell or hold?
CERo Therapeutics has no consensus analysts rating.
CERo Therapeutics has no consensus analysts rating.
What are the forecast for CERO stock price target?
According to ValueRays Forecast Model, CERO CERo Therapeutics will be worth about 3.5 in January 2026. The stock is currently trading at 3.70. This means that the stock has a potential downside of -6.22%.
According to ValueRays Forecast Model, CERO CERo Therapeutics will be worth about 3.5 in January 2026. The stock is currently trading at 3.70. This means that the stock has a potential downside of -6.22%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3.5 | -6.2% |